Proteomics

Dataset Information

0

STAT3 contributes to cisplatin resistance, modulating EMT markers and the mTOR signaling in lung adenocarcinoma cells .

ABSTRACT: Lung cancer is the second leading cause of cancer death worldwide and is strongly associated with cisplatin resistance. The transcription factor STAT3 is constitutively activated in cancer cells and coordinates critical cellular processes as survival, self-renewal, and inflammation. In several types of cancer, STAT3 controls the development, immunogenicity, and malignant behavior of tumor cells while dictates the responsiveness to radio- and chemotherapy. It is known that STAT3 phosphorylation on Ser727 by mTOR is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. In this study, using a proteomic label-based approach, we reveal important targets and signaling pathways increased and decreased in cisplatin-resistant A549 lung adenocarcinoma cells.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Adriana Franco Paes Leme  

LAB HEAD: Adriana Franco Paes Leme

PROVIDER: PXD025778 | Pride | 2022-02-17

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
02ago_FernandoSmb_silac_1_1.raw Raw
02ago_FernandoSmb_silac_1_10.raw Raw
02ago_FernandoSmb_silac_1_2.raw Raw
02ago_FernandoSmb_silac_1_3.raw Raw
02ago_FernandoSmb_silac_1_4.raw Raw
Items per page:
1 - 5 of 32
altmetric image

Publications

Lung cancer is the second leading cause of cancer death worldwide and is strongly associated with cisplatin resistance. The transcription factor signal transducer and activator of transcription 3 (STAT3) is constitutively activated in cancer cells and coordinates critical cellular processes as survival, self-renewal, and inflammation. In several types of cancer, STAT3 controls the development, immunogenicity, and malignant behavior of tumor cells while it dictates the responsiveness to radio- an  ...[more]

Similar Datasets

Proteomics Metformin impairs cisplatin effects in cell size and proliferation of A549 lung cancer cells, modulating the mTOR and other metabolic pathways.
2021-09-09 | PXD017645 | Pride
Transcriptomics RT-PCR profiling analysis of microRNA expression in cisplatin-resistant cancer
2021-03-12 | GSE168707 | GEO
Transcriptomics Gene expression data from human NSCLC U1810 residual clones 9 days after a one-hour pulse treatment with cisplatin
2014-04-04 | E-GEOD-48244 | biostudies-arrayexpress
Transcriptomics The STAT3 induced ITGB4 overexpression represses p53 to reduce the sensitivity of bladder cancer to cisplatin
2024-06-07 | GSE268855 | GEO
Transcriptomics Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (miRNA)
2013-01-15 | E-GEOD-43249 | biostudies-arrayexpress
Transcriptomics Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (lncRNA and mRNA)
2013-01-15 | E-GEOD-43493 | biostudies-arrayexpress
Transcriptomics Disruption of STAT3 signaling promotes KRAS induced lung tumorigenesis
2015-02-05 | E-GEOD-52798 | biostudies-arrayexpress
Transcriptomics The translational landscape of mTOR signaling steers cancer initiation and metastasis
2012-02-28 | E-GEOD-35469 | biostudies-arrayexpress
Proteomics Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small cell lung cancer
2019-11-12 | PXD010680 | Pride
Transcriptomics RNA-seq analysis of control and Myc-induced U2OS cells
2015-11-04 | E-GEOD-66789 | biostudies-arrayexpress